Literature DB >> 1581897

Effects of liarozole, a new antitumoral compound, on retinoic acid-induced inhibition of cell growth and on retinoic acid metabolism in MCF-7 human breast cancer cells.

W Wouters1, J van Dun, A Dillen, M C Coene, W Cools, R De Coster.   

Abstract

Liarozole is a new imidazole derivative with antitumoral properties. Effects of the compound alone and in combination with all-trans-retinoic acid on proliferation of MCF-7 human breast cancer cells were examined using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide assay. Following 9 days of drug exposure, MCF-7 cell growth was concentration dependently inhibited by all-trans-retinoic acid (drug concentration resulting in 50% growth inhibition, 2 x 10(-8) M), while liarozole at 10(-5) M inhibited cell growth by only 35%. When MCF-7 cells were incubated with a combination of all-trans-retinoic acid and liarozole, the antiproliferative effect of all-trans-retinoic acid was clearly enhanced. This enhancement was dependent on the liarozole concentration and was more than 10-fold. A combination of 10(-8) M all-trans-retinoic acid and 10(-6) M liarozole resulted in a greater antiproliferative effect than that obtained with 10(-7) M all-trans-retinoic acid alone. When MCF-7 cells were incubated for 4 h with [3H]all-trans-retinoic acid, the radioactivity in the supernatant consisted of unaltered retinoid. However, when cells had been pretreated with 10(-6) M all-trans-retinoic acid overnight, they were able to substantially metabolize [3H]all-trans-retinoic acid during a subsequent 4-h incubation. High-performance liquid chromatography analysis of the supernatants revealed that the reaction products consisted mainly of very polar metabolites. Liarozole inhibited the metabolism of all-trans-retinoic acid in MCF-7 cells with 10(-5) M liarozole reducing the amount of polar metabolites by 87%. It is concluded that the enhancement by liarozole of the antiproliferative effects of retinoic acid on MCF-7 human breast cancer cells is probably due to inhibition of retinoic acid metabolism. Further research into these effects in MCF-7 cells as well as in other cancer cell lines will provide more information concerning the exact mechanism of action of liarozole and the use of inhibitors of retinoid metabolism in cancer treatment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1581897

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

Review 1.  Breast cancer therapies in development. A review of their pharmacology and clinical potential.

Authors:  D de Valeriola; A Awada; J A Roy; A Di Leo; L Biganzoli; M Piccart
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

2.  First chemical feature-based pharmacophore modeling of potent retinoidal retinoic acid metabolism blocking agents (RAMBAs): identification of novel RAMBA scaffolds.

Authors:  Puranik Purushottamachar; Jyoti B Patel; Lalji K Gediya; Omoshile O Clement; Vincent C O Njar
Journal:  Eur J Med Chem       Date:  2011-11-17       Impact factor: 6.514

3.  Liarozole.

Authors:  H M Bryson; A J Wagstaff
Journal:  Drugs Aging       Date:  1996-12       Impact factor: 3.923

4.  Substrate specificity and ligand interactions of CYP26A1, the human liver retinoic acid hydroxylase.

Authors:  Jayne E Thatcher; Brian Buttrick; Scott A Shaffer; Jakob A Shimshoni; David R Goodlett; Wendel L Nelson; Nina Isoherranen
Journal:  Mol Pharmacol       Date:  2011-04-26       Impact factor: 4.436

Review 5.  Therapeutic potential of the inhibition of the retinoic acid hydroxylases CYP26A1 and CYP26B1 by xenobiotics.

Authors:  Cara H Nelson; Brian R Buttrick; Nina Isoherranen
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

6.  Modulation of all-trans retinoic acid pharmacokinetics by liarozole.

Authors:  V A Miller; J R Rigas; J R Muindi; W P Tong; E Venkatraman; M G Kris; R P Warrell
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Study on cytochrome p-450 dependent retinoic Acid metabolism and its inhibitors as potential agents for cancer therapy.

Authors:  Mobasher Ahmad
Journal:  Sci Pharm       Date:  2011-08-12

8.  Induction of the oxidative catabolism of retinoid acid in MCF-7 cells.

Authors:  M D Krekels; A Verhoeven; J van Dun; W Cools; C Van Hove; L Dillen; M C Coene; W Wouters
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Effects of liarozole fumarate (R85246) in combination with tamoxifen on N-methyl-N-nitrosourea (MNU)-induced mammary carcinoma and uterus in the rat model.

Authors:  Paul E Goss; Kathrin Strasser-Weippl; Shangle Qi; Haiqing Hu
Journal:  BMC Cancer       Date:  2007-01-31       Impact factor: 4.430

10.  Retinoid metabolism and all-trans retinoic acid-induced growth inhibition in head and neck squamous cell carcinoma cell lines.

Authors:  B J Braakhuis; I Klaassen; B M van der Leede; J Cloos; R H Brakenhoff; M P Copper; T Teerlink; H F Hendriks; P T van der Saag; G B Snow
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.